Efficacy and Safety of Two Doses of HIL-214 in Children

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

3,084

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

December 28, 2023

Study Completion Date

September 30, 2024

Conditions
Gastroenteritis
Interventions
BIOLOGICAL

HIL-214

2 injections - given on Day 1 and the second given between Day 29 - Day 57

BIOLOGICAL

Placebo

2 injections - given on Day 1 and the second given between Day 29 - Day 57

Trial Locations (17)

11102

Hospital General Regional Marcelino Velez Santana, Santo Domingo

15024

Instituto de Investigacion Nutricional, Lima

77065

DM Clinical Research, Houston

760042

Cntro de Estudios en Infectologia Pediatrica (CEIP), Santiago de Cali

Unknown

Policlinico Social del Norte, Bogotá

Hospital Pediátrico Dr. Hugo Mendoza, Santo Domingo

CAIMED - Dominican Center for Clinical Studies, Santo Domingo

Clínica Cruz Jiminian, Santo Domingo

Fundacion Dominicana de Perinatologia Pro Bebe, Santo Domingo

Demedica, San Pedro Sula

INVERIME - Inversiones en Investigación Medica, Tegucigalpa

Investigación Sin Limite, Tegucigalpa

CEVAXIN La Chorrera, La Chorrera

CEVAXIN Av. México, Panama City

Clinical Research Puerto Rico, Guayama

00507

CEVAXIN David, David

00831

CEVAXIN 24 Decembre, Panama City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HilleVax

INDUSTRY